AVITA Medical to Announce Third Quarter 2024 Financial Results
AVITA Medical (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company specializing in wound care management and skin restoration devices, has announced it will release its third quarter 2024 financial results on Thursday, November 7, 2024, after the U.S. financial markets close. The company will host a conference call and webcast at 1:30 p.m. Pacific Time on the same day (8:30 a.m. AEDT on November 8, 2024) to discuss the results and recent business highlights.
Investors can access the live webcast through the Events & Presentations section of AVITA Medical's website. For telephone participation, pre-registration is required. A replay of the webcast will be available on the Investor Relations website shortly after the event.
AVITA Medical (NASDAQ: RCEL, ASX: AVH), un azienda di medicina rigenerativa in fase commerciale specializzata nella gestione delle ferite e nei dispositivi per il ripristino della pelle, ha annunciato che pubblicherà i risultati finanziari del terzo trimestre 2024 giovedì 7 novembre 2024, dopo la chiusura dei mercati finanziari statunitensi. L'azienda ospiterà una videoconferenza e un webcast alle 13:30 ora del Pacifico lo stesso giorno (8:30 ora AEDT dell'8 novembre 2024) per discutere i risultati e i recenti punti salienti dell'attività.
Gli investitori possono accedere al webcast live attraverso la sezione Eventi & Presentazioni del sito web di AVITA Medical. Per partecipazione telefonica, è necessaria una pre-registrazione. Una registrazione del webcast sarà disponibile sul sito web delle Relazioni con gli Investitori poco dopo l'evento.
AVITA Medical (NASDAQ: RCEL, ASX: AVH), una empresa de medicina regenerativa en etapa comercial especializada en el manejo de heridas y dispositivos para la restauración de la piel, ha anunciado que publicará sus resultados financieros del tercer trimestre de 2024 el jueves 7 de noviembre de 2024, después del cierre de los mercados financieros de EE. UU. La empresa llevará a cabo una videoconferencia y un webcast a la 1:30 p.m. hora del Pacífico el mismo día (8:30 a.m. AEDT del 8 de noviembre de 2024) para discutir los resultados y los aspectos destacados recientes de la empresa.
Los inversores pueden acceder al webcast en vivo a través de la sección de Eventos y Presentaciones del sitio web de AVITA Medical. Para participar por teléfono, se requiere una preinscripción. Una repetición del webcast estará disponible en el sitio web de Relaciones con Inversores poco después del evento.
AVITA Medical (NASDAQ: RCEL, ASX: AVH)는 상업 단계의 재생 의학 회사로, 상처 관리 및 피부 복원 장치 전문 회사입니다. 이 회사는 2024년 11월 7일 목요일 미 금융 시장이 닫힌 후 2024년 3분기 재무 결과를 발표할 것이라고 발표했습니다. 같은 날 오후 1시 30분 태평양 표준시(2024년 11월 8일 오전 8시 30분 AEDT)에 결과 및 최근 비즈니스 하이라이트를 논의하기 위한 컨퍼런스 콜 및 웨브캐스트를 개최합니다.
투자자는 AVITA Medical 웹사이트의 이벤트 및 발표 섹션을 통해 실시간 웨브캐스트에 접속할 수 있습니다. 전화 참여를 원할 경우 사전 등록이 필요합니다. 웨브캐스트의 재생은 행사 직후 투자자 관계 웹사이트에서 확인할 수 있습니다.
AVITA Medical (NASDAQ: RCEL, ASX: AVH), une entreprise de médecine régénérative en phase commerciale spécialisée dans la gestion des blessures et les dispositifs de restauration de la peau, a annoncé qu'elle publiera ses résultats financiers du troisième trimestre 2024 le jeudi 7 novembre 2024, après la fermeture des marchés financiers américains. L'entreprise organisera un appel conférence et un webinaire à 13h30, heure du Pacifique, le même jour (8h30 AEDT le 8 novembre 2024) pour discuter des résultats et des dernières nouvelles commerciales.
Les investisseurs peuvent accéder au webinaire en direct via la section Événements & Présentations du site Web d'AVITA Medical. Pour participer par téléphone, une pré-inscription est requise. Un replay du webinaire sera disponible sur le site des relations investisseurs peu après l'événement.
AVITA Medical (NASDAQ: RCEL, ASX: AVH), ein kommerzielle regenerativen Medizin-Unternehmen, das auf Wundmanagement und Hautwiederherstellungsgeräte spezialisiert ist, hat bekannt gegeben, dass es am Donnerstag, den 7. November 2024, nach dem Schluss der US-Finanzmärkte seine Finanzergebnisse für das dritte Quartal 2024 veröffentlichen wird. Das Unternehmen wird am selben Tag um 13:30 Uhr pazifischer Zeit (8:30 Uhr AEDT am 8. November 2024) eine Telefonkonferenz und ein Webcast veranstalten, um die Ergebnisse und die jüngsten geschäftlichen Highlights zu besprechen.
Investoren können über den Abschnitt Veranstaltungen & Präsentationen der AVITA Medical-Website auf den Live-Webcast zugreifen. Für die telefonische Teilnahme ist eine Voranmeldung erforderlich. Eine Aufzeichnung des Webcasts wird kurz nach der Veranstaltung auf der Website für Investorenbeziehungen verfügbar sein.
- None.
- None.
VALENCIA, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that it will report its third quarter 2024 financial results after the close of the U.S. financial markets on Thursday, November 7, 2024. AVITA Medical will host a conference call and webcast that day at 1:30 p.m. Pacific Time (Friday, November 8, 2024, at 8:30 a.m. Australian Eastern Daylight Time) to discuss its financial results and recent business highlights.
The live webcast will be accessible under the Events & Presentations section of the AVITA Medical website at ir.avitamedical.com. To participate by telephone, please register in advance to receive dial-in details and a personal PIN using this link. A replay of the webcast will be available shortly after the live event on the Investor Relations website.
About AVITA Medical, Inc.
AVITA Medical® is a commercial-stage regenerative medicine company transforming the standard of care in wound care management and skin restoration with innovative devices. At the forefront of our platform is the RECELL® System, approved by the U.S. Food and Drug Administration for the treatment of thermal burn wounds and full-thickness skin defects, and for repigmentation of stable depigmented vitiligo lesions. RECELL harnesses the regenerative properties of a patient’s own skin to create Spray-On Skin™ Cells, delivering a transformative solution at the point-of-care. This breakthrough technology serves as the catalyst for a new treatment paradigm enabling improved clinical outcomes. In the United States, AVITA Medical also holds the exclusive rights to market, sell, and distribute PermeaDerm®, a biosynthetic wound matrix, and Cohealyx™, an AVITA Medical-branded collagen-based dermal matrix.
In international markets, the RECELL System is approved to promote skin healing in a wide range of applications including burns, full-thickness skin defects, and vitiligo. The RECELL System is TGA-registered in Australia, has received CE-mark approval in Europe, and has PMDA approval in Japan.
To learn more, visit www.avitamedical.com.
Authorized for release by the Chief Financial Officer of AVITA Medical, Inc.
FAQ
When will AVITA Medical (RCEL) report its Q3 2024 financial results?
How can investors access AVITA Medical's (RCEL) Q3 2024 earnings call?
What time is AVITA Medical's (RCEL) Q3 2024 earnings conference call?
Will there be a replay available for AVITA Medical's (RCEL) Q3 2024 earnings call?
